Can Pharmacologic Therapy Induce Histologic Improvement in Non-alcoholic Steatohepatitis?
The Korean Journal of Gastroenterology, 2016 Articles: Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-cirrhotic, Non-alcoholic Steatohepatitis (FLINT): a Multicentre, Randomised, Placebo-controlled Trial (Lancet 2015;385:956-965) Liraglutide Safety and Efficacy in Patients with Non ...
Nae-Yun Heo
doaj +1 more source
Pharmacotherapy for Nonalcoholic Fatty Liver Disease [PDF]
, 2015 Lifestyle modifications and optimization of the management of cardiometabolic comorbidities are currently the mainstay of treatment for patients with nonalcoholic fatty liver disease.
Chalasani, Naga, Gawrieh, Samer
core +2 more sources
Fine-tuning of SIRT1 expression is essential to protect the liver from cholestatic liver disease [PDF]
, 2019 Cholestasis comprises aetiologically heterogeneous conditions characterized by accumulation of bile acids in the liver that actively contribute to liver damage.
Banales, Jesus M +21 more
core +4 more sources
miR-22 inhibition reduces hepatic steatosis via FGF21 and FGFR1 induction
JHEP Reports, 2020 Background & Aims: Metabolism supports cell proliferation and growth. Surprisingly, the tumor suppressor miR-22 is induced by metabolic stimulators like bile acids. Thus, this study examines whether miR-22 could be a metabolic silencer.
Ying Hu +5 more
doaj +1 more source
Impact of Primary and Secondary Bile Acids on Clostridioides difficile Infection
Polish Journal of Microbiology, 2022 Primary bile acids (BAs), synthesized from cholesterol in the liver, after their secretion with bile into the intestinal lumen, are transformed by gut microbiota to secondary BAs. As natural detergents, BAs play a key role in the digestion and absorption
Łukawska Agata, Mulak Agata
doaj +1 more source
Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury
Cells, 2021 Recent studies on liver disease burden worldwide estimated that cirrhosis is the 11th most common cause of death globally, and there is a great need for new therapies to limit the progression of liver injuries in the early stages.
Anca D. Petrescu, Sharon DeMorrow
doaj +1 more source
Rethinking the bile acid/gut microbiome axis in cancer [PDF]
, 2017 Dietary factors, probiotic agents, aging and antibiotics/medicines impact on gut microbiome composition leading to disturbances in localised microbial populations.
Caparros-Martin, Jose A. +4 more
core +1 more source
Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
Acta Pharmaceutica Sinica B, 2019 Obeticholic acid (OCA), the first FXR-targeting drug, has been claimed effective in the therapy of liver fibrosis. However, recent clinical trials indicated that OCA might not be effective against liver fibrosis, possibly due to the lower dosage to ...
Jiyu Zhou +9 more
doaj +1 more source
Bile acids at the cross-roads of gut microbiome–host cardiometabolic interactions [PDF]
, 2017 This work is supported in part by the APC Microbiome Institute (under Science Foundation Ireland [SFI] Grant Number: SFI/12/RC/2273) and by Enterprise Ireland Commercialization Fund (Contract Reference: CF/2013/3030A/B).peer-reviewedWhile basic and ...
Caplice, Noel M +2 more
core +3 more sources
Evolving Role for Pharmacotherapy in NAFLD/NASH
Clinical and Translational Science, 2021 Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent, dynamic disease that occurs across the age spectrum and can lead to cirrhosis and hepatocellular carcinoma.
Suzanna L. Attia +2 more
doaj +1 more source